RENAAL: Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan.
The renoprotective effects of ACE inhibitors (CSG Captopril Trial, 1993) had been established prior to the RENAAL study. This was to evaluate the renoprotective effects of angiotensin receptor blockers
Losartan conferred significant renal benefits in patients with type 2 diabetes and nephropathy, and it were generally well tolerated.
Brenner BM, Cooper ME, de Zeeuw D, Grunfeld JP, Keane WF, Kurokawa K, McGill JB, Mitch WE, Parving HH, Remuzzi G, Ribeiro AB, Schluchter MD, Snavely D, Zhang Z, Simpson R, Ramjit D, Shahinfar S; RENAAL Study Investigators. The losartan renal protection study–rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J Renin Angiotensin Aldosterone Syst. 2000 Dec;1(4):328-35